SeaStar Medical Holding Corporation (ICU)

NCM – Real vaqt narxi. Valyuta: USD

4.84

+0.26 (5.68%)

Yopilishda: May 12, 2026, 4:00 PM EDT

4.94

+0.10 (2.06%)

Bozordan keyin: May 12, 2026, 7:57 PM EDT

06.05.2026

SeaStar Medical to Report First Quarter Financial Results on May 13, 2026

DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 13, 2026, and host a webcast and conference call to discuss its financial results and business progress.

30.03.2026

SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026

Results from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data

25.03.2026

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Added top-rated children's hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI Advanced pipeline indications with initiation of cardio-renal clinical trial Webcast today at 4:30 pm Eastern Time DENVER, March 25, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2025, and provided business updates on key initiatives. “In 2025, we broadened our customer base of top-ranked children's hospitals, continued enrollment in the NEUTRALIZE-AKI pivotal clinical trial, and advanced our pipeline with the initiation of the cardio-renal clinical trial of our selective cytopheretic device (SCD) therapy,” said Eric Schlorff, CEO of SeaStar Medical.

18.03.2026

SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026

DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026, and host a webcast and conference call to discuss its financial results and business progress.

09.03.2026

SeaStar Medical to Present at the Life Sciences Investor Forum on March 11th

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com

05.03.2026

SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

Completion of enrollment marks a key milestone toward satisfying FDA post-approval requirements Completion of enrollment marks a key milestone toward satisfying FDA post-approval requirements

09.02.2026

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

Strong survival data extending to 90 days Real-world experience shows results consistent with clinical trial data Favorable safety profile – no device-related adverse events DENVER, Feb. 09, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today the publication of early post-approval clinical experience from the use of the QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in the prestigious, peer-reviewed journal Pediatric Nephrology . The publication, co-authored by leading experts including Stuart Goldstein, Kelli Krallman, Meredith Harris, Rajit Basu, David Askenazi, Shina Menon, Matt Zinter, Steven Gorga, and H.

Videolar

No Data

There is no data to display

Press-relizlar

30.03.2026

SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026

Results from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data

25.03.2026

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

05.03.2026

SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

Completion of enrollment marks a key milestone toward satisfying FDA post-approval requirements Completion of enrollment marks a key milestone toward satisfying FDA post-approval requirements

09.02.2026

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

SeaStar Medical Holding Corporation (ICU)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

SeaStar Medical Holding Corporation (ICU)

SeaStar Medical to Report First Quarter Financial Results on May 13, 2026

SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026

SeaStar Medical to Present at the Life Sciences Investor Forum on March 11th

SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

Videolar

No Data

Press-relizlar

SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

SeaStar Medical to Report First Quarter Financial Results on May 13, 2026

SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026

SeaStar Medical to Present at the Life Sciences Investor Forum on March 11th

SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

Videolar

No Data

Press-relizlar

SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

Search stocks

SeaStar Medical Holding Corporation (ICU)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

SeaStar Medical Holding Corporation (ICU)

SeaStar Medical to Report First Quarter Financial Results on May 13, 2026

SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026

SeaStar Medical to Present at the Life Sciences Investor Forum on March 11th

SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

Videolar

No Data

Press-relizlar

SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

SeaStar Medical to Report First Quarter Financial Results on May 13, 2026

SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026

SeaStar Medical to Present at the Life Sciences Investor Forum on March 11th

SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

Videolar

No Data

Press-relizlar

SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)